As many pharmaceutical companies have expanded their traditional research and development (R&D) focus beyond small molecules to include biotechnology products, patients and the industry, have benefited from this change. The number of biotech compounds in clinical trials grew by 155 percent between 2001 and 2012, and investment in biotech research increased from $10.5 billion to $103 billion during the same time period, according to an analysis by the Tufts Center for the Study of Drug Development (Tufts CSDD). This massive advancement in R&D has led to more treatment potential for patients.
Embracing this innovation in research is essential for medical progress. Over the past decade, Celgene has built a strong reputation as a leader in hematology. But rather than resting on those laurels, Celgene is leading the charge in finding transformative solutions for patients who have other unmet treatment needs. In fact, between 2005 and 2010, the Company reinvested over 30 percent of its revenues—more than twice the pharmaceutical industry average—into research and development.
“Our programs focus on innovations that will deliver high impact therapies, whether in orphan diseases, or in settings where we can drive major shifts in therapeutic benefit in favor of patients,” Tom Daniel, president of Celgene Research and Early Development, said. “We are applying disruptive technologies, coupled with deep clinical insights to wage campaigns in disease settings where the unmet need is greatest.”
As of 2012, the company supported more than 500 clinical trials examining at least 25 unique compounds. And last year, approximately 28,000 patients were actively enrolled in Celgene trials studying more than 50 different investigatory uses. The corresponding research is aimed at addressing the unmet needs of 25 million people worldwide in more than 30 disease areas.
The promising pipeline is nurtured by Celgene scientists, whose imaginations are helping to transform modern medical technologies such as epigenetics and cancer metabolism, cancer immunotherapy, disruptive technologies and next-generation biologics into innovative treatments for solid tumors, blood cancers and immune diseases.
Celgene has dedicated, collaborative research facilities in the United States in California, New Jersey and Massachusetts and in Seville, Spain. Their diverse research platforms address disease via protein homeostasis, the TORK pathway, tumor progenitors, immune cell genetic engineering, epigenetics and cancer metabolism. Emerging projects include a biologics platform and treatments for fibrosis diseases and severe autoimmune diseases.
By focusing on unmet medical needs, Celgene has become a pharmaceutical leader in developing drugs for orphan diseases. And as with the more common diseases that Celgene therapies address, the goal is always to transform deadly diseases into chronic, manageable disorders, in line with their commitment to improving the lives of patients worldwide.